- Home
- » Tags
- » Palbociclib
Top View
- CDK4/6 Inhibitor Palbociclib Enhances the Effect of Pyrotinib in HER2
- CDK4/6 and MAPK—Crosstalk As Opportunity for Cancer Treatment
- Antibody–Drug Conjugates for Cancer Therapy
- New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer
- View of This Manuscript
- Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
- NCCN Guidelines for Patients Metastatic Breast Cancer
- Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid- Derived Hematologic Malignancies
- New Approaches in Breast Cancer Treatment
- As of October 31, 2017
- Ibrance (Palbociclib)
- CDK4/6 and Autophagy Inhibitors Synergistically Induce Senescence in Rb Positive Cytoplasmic Cyclin E Negative Cancers
- Pharmacology Update
- Pfizer Oncology Analyst Call
- An Advanced Refractory Breast Cancer Patient with Human Epidermal Growth Factor Receptor 2 Discordance: a Case Report
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
- Palbociclib: Drug Information
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- Acquired Resistance to Antibody-Drug Conjugates
- CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
- Palbociclib (PD-0332991) Advanced Breast Cancer A5481053 Final Protocol, 23 July 2015
- IBRANCE® (Palbociclib) Tablets, for Oral Use • Embryo-Fetal Toxicity: IBRANCE Can Cause Fetal Harm
- Northern Arizona Clinical Trials
- Systemic Therapy Update
- Abemaciclib, a Selective€CDK4/6€Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in Vitro and in Vivo
- Palbociclib (Ibrance) | Breast Cancer Now
- Australian Public Assessment for Palbociclib [Ibrance]
- Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy
- 1 Phase II Safety Study of Palbociclib in Combination with Letrozole Or
- Oncology Therapy for the Generalist
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Functional Genomics for Breast Cancer Drug Target Discovery ✉ Tetsuro Yoshimaru 1, Yusuke Nakamura2 and Toyomasa Katagiri 1
- Breast Cancer Immunotherapy
- 4611.Full-Text.Pdf
- 207103Orig1s000
- Cyclin-Dependent Protein Kinase Inhibitors Including Palbociclib As
- Cyclin E1 Inhibition Can Overcome Sorafenib Resistance In
- ABOUT IBRANCE® (Palbociclib)
- Development of CDK4/6 Inhibitors: a Five Years Update
- Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
- Engaging the Body's Natural Defense Against Cancer
- Recent Developments in HER2-Directed Therapy in Breast Cancer
- Lapatinib: Drug Information
- Phase 1B Clinical Trial of Ado-Trastuzumab Emtansine and Ribociclib for HER2-Positive Metastatic Breast Cancer
- HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2- Positive and HER2-Mutated Breast Cancer
- C-Myc Regulates the Sensitivity of Breast Cancer Cells to Palbociclib
- 1 Mtorc1 Inhibition Induces Resistance To
- Smart Approaches for the Effective Treatment of Breast Cancer
- The Exciting New Field of HER2-Low Breast Cancer Treatment
- New Treatment Options for Acute Myeloid Leukemia in 2019
- Combination of Th1 Cytokines Plus Small Molecule Kinase
- Ibrance® (Palbociclib) P&T Approval Date 4/2015, 4/2016, 3/2017, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021 Effective Date 8/1/2021; Oxford Only: 8/1/2021
- Palbociclib (PD-0332991), a Selective CDK4/6 Inhibitor, Restricts
- News & Views February 10, 2019
- HER2-Positive Metastatic Breast Cancer: a Comprehensive Review
- Blinatumomab (Blincyto®)
- Targeting Cyclin-Dependent Kinases for the Treatment of Pulmonary Arterial Hypertension
- Palbociclib (PD-0332991), a Selective CDK4/6 Inhibitor, Restricts
- 1541-7786.Mcr-17-0468.Full-Text.Pdf
- Full Text (PDF)
- Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib in Combination with an Aromatase Inhibitor Or Fulv
- (Palbociclib). Ibrance Formerly Known As LEE011)In Combination Tagrisso
- Title: P27 Allosterically Activates Cyclin-Dependent Kinase 4 and Antagonizes Palbociclib Inhibition